GBS vs. TELA, BWAY, KRMD, BLUA, SRTS, HSAQ, ALUR, PDEX, NSPR, and NVNO
Should you be buying GBS stock or one of its competitors? The main competitors of GBS include TELA Bio (TELA), BrainsWay (BWAY), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), InspireMD (NSPR), and enVVeno Medical (NVNO). These companies are all part of the "surgical & medical instruments" industry.
TELA Bio (NASDAQ:TELA) and GBS (NYSE:GBS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
TELA Bio has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, GBS has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
94.4% of TELA Bio shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 6.0% of TELA Bio shares are held by company insiders. Comparatively, 0.3% of GBS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, GBS had 5 more articles in the media than TELA Bio. MarketBeat recorded 6 mentions for GBS and 1 mentions for TELA Bio. GBS's average media sentiment score of 1.87 beat TELA Bio's score of 0.01 indicating that TELA Bio is being referred to more favorably in the media.
GBS has a net margin of 0.00% compared to GBS's net margin of -63.82%. TELA Bio's return on equity of -85.64% beat GBS's return on equity.
GBS has lower revenue, but higher earnings than TELA Bio. GBS is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
TELA Bio received 52 more outperform votes than GBS when rated by MarketBeat users.
TELA Bio currently has a consensus price target of $13.00, suggesting a potential upside of 135.08%. Given GBS's higher possible upside, research analysts clearly believe TELA Bio is more favorable than GBS.
Summary
TELA Bio beats GBS on 9 of the 16 factors compared between the two stocks.
Get GBS News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
